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ABSTRACT 
There is two-way communication between the gut and the brain. The condition of the quality and quantity of microbiota in the gut greatly affects 
the communication process or commonly known as the microbiota-gut-brain axis. Acute ischemic stroke can affect the quality and quantity of 
microbiota in the gut, which leads to intestinal dysbiosis. Thus, it might produce an inflammatory response that can change immune homeostatic. 
This can lead to poor clinical outcomes and neurologic function and an increase in mortality. Dysbiosis is a condition where there are qualitative 
and quantitative changes in the composition, distribution, and metabolic activity of intestinal microbiota which have a detrimental effect on human 
health, in other words, there is a decrease in the number of probiotic bacteria in the gut, which provide health benefits. The conditions for a good 
probiotic are that the probiotics have to be kept alive in the digestive tract to obtain health benefits. The approach taken to keep these bacteria alive 
is the use of prebiotics. Prebiotics are components of food that cannot be digested by the digestive tract enzymatically. Thus, they are fermented by 
microbiota in the large intestine to produce metabolites, one of which is short-chain fatty acids (SCFA) as a product of fermentation. SCFA (Short 
Chain Fatty Acid) or short-chain fatty acids play a neuroprotective role, synthesizing neurotransmitters and modulating the immune system. 
Therefore, this review explains how stroke affects the quantity and quality of microbiota in the gut in the communication process of the microbiota-
gut-brain axis and the role of prebiotics in improving dysbiosis. Hence, it can provide better post-stroke clinical outcomes. 
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INTRODUCTION 
The incidence of ischemic stroke accounts for about 80% of all strokes 
[1]. The main causes of ischemic stroke are thrombosis, embolism, and 
systemic hypoperfusion. All of these cause disruptions of cerebral 
blood flow. Normal brain tissue receives a blood flow of 50-55 
ml/100g/min. When ischemia occurs in the brain, the cerebral blood 
flow decreased, results in an inadequate supply of oxygen and glucose, 
which triggers the pathophysiological process of stroke. The 
pathophysiology of stroke is very complex and involves various 
processes, such as energy failure, excitotoxicity, oxidative stress, 
damage to the blood-brain barrier, inflammation, necrosis or 
apoptosis, and so on [2, 3], referring to as the ischemic cascade. 
Based on data from World Health Organization (WHO) in 2016, 
there were 5.5 million deaths caused by cerebrovascular disease 
worldwide (2.7 million deaths from ischemic strokes and 2.8 million 
deaths from hemorrhagic strokes) [4]. Eastern Europe, East Asia, as 
well as parts of Southeast Asia, Central Asia, and Africa have the 
highest death rates from stroke [4]. In Indonesia, the prevalence of 
stroke increased from 7% in 2013 to 10.9% in 2018 and increased 
with age [5]. Based on the data basis of health research [6], number 
of patients who have been diagnosed stroke are 2,137,941 patients 
(12.1%). Stroke patients were mostly found in the age group of 45-
54 y, 55-64 y, and 65-74 y [7]. 
Several previous studies have shown that the gut-brain axis 
mechanism plays an important role in the pathophysiological process 
of ischemic stroke [7, 8]. Ischemic conditions cause dysbiosis and 
disruption of the intestinal barrier [9–11]. Dysbiosis is a condition 
where there are qualitative and quantitative changes in the 
composition, distribution, and metabolic activity of microbes that 
cause detrimental effects on the host [13]. In other words, the number 
of beneficial microbiota (probiotics) is decreased. Microbiota in the 
intestine, especially probiotics, will carry out fermentation to produce 
metabolites, one of which is SCFA (Short Chain Fatty Acid). Several 
studies have reported that SCFA can affect diseases of the central 
nervous system [13, 14]. It can also improve brain function directly 
and indirectly through immunological, endocrine, vagal, and other 
humoral pathways [14]. Moreover, SCFA can improve intestinal 
permeability and the blood-brain barrier [15, 16].  
The conditions for a good probiotic are that the probiotics have to be 
kept alive in the digestive tract to obtain the health benefits from it. 
The approach taken to keep these bacteria alive is the use of 
prebiotics [18]. Prebiotics are food components that cannot be 
digested by the human digestive tract enzymatically. Therefore, they 
might be fermented by the microflora present in the large intestine 
[19]. Prebiotics in the large intestine will support the growth of 
probiotic bacteria and suppress pathogenic bacteria. There are 
various benefits obtained from consuming prebiotics, including 
preventing constipation, a condition of not being able to defecate 
regularly, lowering intestinal pH, and being able to restore the 
microflora in the intestine after changes due to antibiotic use, 
diarrhea, or stress [20]. In general, foodstuff components that have 
prebiotic properties include non-starch polysaccharides (such as 
pectin, cellulose, and xylene), sugars, and oligosaccharides (such as 
lactose, raffinose, fructooligosaccharides, galactooligosaccharides, 
and lactulose) [19, 20].  
Fruits, vegetables, cereals, and several types of plants are potential 
sources of carbohydrates as prebiotics, such as tomatoes, artichokes, 
bananas, asparagus, berries, garlic, onions, chicory, green vegetables, 
nuts, oats, flaxseeds, barley, and wheat flour [23]. Besides, there are 
several artificial prebiotics, such as lactulose, galacto-
oligosaccharides, fructooligosaccharides, maltooligosaccharides, 
cyclodextrins, and lactosaccharides. Fructans, such as inulin and 
oligofructose, are the most commonly used and effective for 
producing many probiotic species [22, 23]. Prebiotics can potentially 
be beneficial for health, especially in relation to maintaining brain 
function in ischemic conditions. This review discusses various 
aspects of prebiotics, including the important role of prebiotics in 
acute ischemic stroke. 
Source of information 
For writing this comprehensive research review on prebiotic uses 
for acute ischemic stroke, various databases were searched. For the 
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collection of relevant information, specific terms such as medical 
subject headings (MeSH) and key text words, such as “stroke 
pathophysiology”, “gut dysbiosis”, “microbiota-gut-brain axis”, 
“prebiotic and acute ischemic stroke”, and “role of SCFA in gut 
dysbiosis” published till 2020 were used in MEDLINE. Most 
especially for retrieving all articles pertaining to the prebiotic uses 
for acute ischemic stroke, electronic bibliographic databases were 
searched and abstracts of published studies with relevant 
information on the prebiotis/SCFA mechanism on the gut-brain axis 
were collected. Furthermore, additional references were included 
through searching the references cited by the studies done on the 
present topic. Relevant terms were used individually and in 
combination to ensure an extensive literature search. For updating 
the information about a subject and incorporation of recent 
knowledge, relevant research articles, books, conference 
proceedings’ and public health organization survey reports were 
selected and collated based on the broader objective of the review. 
This was achieved by searching databases, including SCOPUS, Web 
of Science, EMBASE, Swiss Prot, Pubmed, and Google scholar. From 
this common methodology, discoveries and findings were identified 
and summarized in this final review. 
The microbiota-gut-brain communication 
Several studies on the human body have shown that stroke can 
change the composition of the gut microbiota. A cohort study in 
Japan that analyzed the gut microbiota and organic acids present in 
the feces of subjects with stroke compared to controls gave results 
that ischemic stroke altered the diversity of several bacterial species. 
This change was independent of age, type 2 diabetes mellitus, and 
hypertension. Increased composition of Lactobacillus ruminis was 
positively correlated with inflammatory markers in stroke patients. 
This change in microbiota was accompanied by a 13% reduction in 
total organic acid with increased and decreased SCFAs of valeric and 
acetic acid by 54% and 18% in patients with stroke, respectively. 
Given that SCFA is a product of bacterial fermentation, it is expected 
that the change in SCFA is the result of changes in microbiota 
composition after stroke. However, in that study, it is also possible 
that the dietary changes in patients with stroke during the stay in 
hospital may have resulted in differences in the microbiota and 
metabolites observed [12]. 
In another study, patients with large-artery atherosclerotic strokes 
or transient ischemic attacks (TIA) were compared with non-stroke 
controls with and without carotid atherosclerotic plaque. In control 
subjects, the gut microbiota was similar regardless of the presence 
or absence of carotid plaque. The streak gut microbiota 
arrangement/TIA showed an increase of several pathogens and 
decreased the number of beneficial bacteria [11]. 
Studies in animal models of stroke have provided further evidence of 
stroke-induced gut dysbiosis and helped identify the mechanisms by 
which stroke affects the gut and microbiota. In the experimental 
animal studied, MCAO (Middle Cerebral Artery Occlusion) was 
carried out in the proximal part to indicate the condition of ischemic 
stroke. Stroke causes intestinal dysbiosis, intestinal paralysis, 
increased intestinal dysbiosis, loss of cholinergic innervation in the 
ileum, and increased sympathetic activity [23, 31, 32]. Loss of 
cholinergic signaling that supports this adrenergic signaling is 
known to increase inflammation in the gut. Increased intestinal 
adrenergic stimulation following MCAO processing was also 
associated with decreased goblet cell counts in the cecum and 
impaired production of the major glycoprotein mucin in 
gastrointestinal mucus [28]. The mucus layer, which acts as a 
protective barrier between the epithelium and the lumen of the 
intestine, is a home for bacteria that helps communication between 
the host and the luminal microbiota. After the proximal MCAO 
process, intestinal permeability and bacterial translocation were 
increased in young and old mice [29]. Therefore, 24 h after proximal 
MCAO was performed, >60% of the microbiota in the lungs was 
deemed to originate from the small intestine [32, 35]. However, an 
increase in bacterial translocation after stroke has not been 
observed in many studies [25]. Overall, intestinal dysbiosis due to 
stroke is the precursor to post-stroke infection, which is a major 
cause of the increased length of stay and mortality after stroke. 
The extent of the interaction mechanism between the gut microbiota 
and non-gastrointestinal organs is still being studied in various 
studies. However, evidence suggests that there is two-way 
communication between the gut, microbiota, and brain. This two-
way communication is known as the microbiota-gut-brain axis. 
Signaling between the brain and gut occurs via neuronal and non-
neuronal mechanisms (fig. 1 and 2). For signaling from the brain to 
the intestine, the intestinal wall receives direct communication 
through parasympathetic and sympathetic nerve fibers or indirectly 
follows stimulation of the enteric nervous system, namely the 
system of nervous connections located in the submucosa and the 
myenteric plexus of the intestine (fig. 2). This neuronal mechanism 
affects intestinal motility, intestinal permeability, microbiota 
composition, and activation of immune cells. Not only direct 
neuronal mechanisms, but the hypothalamic-pituitary-adrenal axis 
is also very important as a communication pathway in response to 
stress (fig. 1). 
 
 
Fig. 1: 2-way communication between gut and brain [9] 
 
Signaling from the gut to the brain is expected to occur through several 
different mechanisms. The first one is through the vagus nerve, which 
consists of 80% afferent fiber and 20% efferent fiver, which has a dual 
role in conveying signals between the intestine and the brain (fig. 2). 
This afferent fiber can be stimulated by microbial compounds, 
metabolites, and hormones (for example, serotonin, cholecystokinin, 
glucagon-like peptide-1, and peptide YY) released by enteroendocrine 
cells from the epithelial layer of the intestine to initiate signaling from 
the intestine to the brain. Stimulation of signals from these afferent 
nerve fibers goes throughout the brain, including the nerve cells in the 
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hypothalamus that regulate the secretion of the pituitary gland and the 
nucleus of the solar nerve tract. Second, immunogenic endotoxin from 
microbiota, such as lipopolysaccharide (LPS), can induce neuronal 
inflammation either directly or through activation of peripheral 
immune cells, which can then migrate to the brain (fig. 1) [23, 24]. 
Third, the microbiota produces or stimulates the release of several 
metabolites, such as neurotransmitters, short-chain fatty acids (SCFA), 
indoles, and bile acids that enter the circulatory system and travel to 
the brain to modulate the function of neurons, microglia, astrocytes, 
and the blood-brain barrier (BBB) [25–27]. 
 
 
Fig. 2: The neuronal mechanism of communication between the brain and the gut. The blue arrows show that the afferent nerve signaling 
from the gut to the brain, white arrows show efferent nerve signaling from the brain to the gut [9] 
 
SCFA, such as acetate, butyrate, and propionate, are the main end 
products of bacterial fermentation of resistant starch and fiber. 
These SCFAs not only function as a source of energy but also have 
vasoactive properties. Moreover, SCFAs affect host cells through 
various mechanisms, including altering histone acetylation and cell 
proliferation, as well as activation of GPCR (G-protein coupled 
receptors). An imbalance in the bacterial composition in the gut or a 
reduction in SCFA-producing bacteria has been described in several 
models of cardiovascular and metabolic disease, including stroke, 
hypertension, obesity, and diabetes mellitus [28–30]. 
As discussed above, the microbiota-gut-brain axis communication is 
two-way communication. Thus, there is increasing evidence that 
stroke alters the gut microbial through signaling from the brain to 
the gut (top-bottom). An imbalance in the composition of the gut 
microbiota can affect the condition of stroke in gut-to-brain 
(bottom-top) signaling. 
Prebiotics 
Prebiotics were first introduced in 1995 by Glenn Gibson and Marcel 
Roberfroid [38]. Prebiotics are "food substances that cannot be 
digested and can stimulate the growth and/or activity of one or 
several bacteria in the large intestine, making them beneficial to 
one's health." According to this definition, only a few compounds 
from the carbohydrate group, such as fructooligosaccharides (FOS), 
inulin, lactulose, and galactooligosaccharides (GOS) can be classified 
as prebiotics. In 2008, the 6th
- Not digested (or only partially digested 
 meeting of the International Scientific 
Association of Probiotics and Prebiotics (ISAPP) defined “prebiotics” 
as “food ingredients that are fermented and produce specific 
changes in the composition and/or activity of the gastrointestinal 
microbiota, thus providing benefits to one’s health” [38]. The 
following criteria are used to classify a compound as prebiotic [38]:  
- Poorly fermented by bacteria in the oral cavity 
- Well fermented by probiotic gut bacteria 
- Not fermented by potential pathogens in the intestine. 
Carbohydrates, like fiber, are prebiotics. Prebiotics and fiber are 
terms used as alternatives to the undigested components of food in 
the digestive tract [39,40]. A significant difference between the two 
terms is that prebiotics is fermented by a certain group of 
microorganisms, whereas fiber is used by most of the gut 
microorganisms [40]. Therefore, taking into account that the 
interchangeability of the terms is not always correct. Prebiotics are 
fibers, but the fiber is not always a prebiotic [41]. 
Some non-starch polysaccharides are fiber, for example, cellulose, 
hemicellulose, pectin, latex, substances obtained from seaweed, as well 
as lactulose, soybean oligosaccharides, inulin, fructooligosaccharides, 
galactooligosaccharides, xylooligosaccharides, and 
isomaltooligosaccharides. Based on the number of monomers, 
prebiotics can be classified as disaccharides, oligosaccharides (3-10 
monomers), and polysaccharides. The most satisfactory criteria for 
prebiotic classification as evidenced by in vitro and in vivo studies are 
oligosaccharides, including fructooligosaccharides (FOS), 
galactooligosaccharides (GOS), isomaltooligosaccharides (IMO), 
xylooligosaccharides (XOS), transgalactooligosccharides (TOS), and 
soybean oligosaccharides (SBOS) [39, 40].  
Furthermore, polysaccharides such as inulin, reflux starch, cellulose, 
hemicellulose, or pectin have the potential to be prebiotic. The use of 
glucooligosaccharides, glucooligosaccharides, lactitol, isomalto-
oligosaccharides, stachyose, raffinose, and saccharose as prebiotics 
requires further study [44]. 
Prebiotics are found in natural products, but they can also be added 
to foods. The purpose of this addition is to increase nutritional value 
and health. Some examples are inulin, fructooligosaccharide, 
lactulose, and galactose, and β-glucan derivatives. These substances 
can function as probiotic media for reproduction. Prebiotics are not 
digested by enzymes and reach the large intestine without change of 
shape, where they are fermented by saccharolytic bacteria (for 
example, genus Bifidobacterium). Prebiotic consumption greatly 
affects the composition of the gut microbiota and its metabolic 
activity [45]. This is due to modulation of lipid metabolism, 
increased calcium absorption, effects on the immunological system, 
and modification of bowel function [45]. The structure of the 
prebiotic molecule determines its physiological effects and the types 
of microorganisms that can utilize it as an energy source [23].  
The mechanism of the beneficial effect of prebiotics on 
immunological function is unclear [46]:  
1. Prebiotics are able to regulate the work of liver lipogenic 
enzymes by influencing the increased production of short-chain fatty 
acids (SCFA), such as propionic acid. 
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2. The production of SCFA (especially butyric acid) as a result of 
fermentation has been identified as a modulator of histone 
acetylation, thereby increasing the availability of many genes for 
transcription factors. 
3. Modulation of mucin production. 
4. FOS and some other prebiotics cause an increase in the number 
of lymphocytes and/or leukocytes in intestinal lymphoid tissue 
(GALT) and peripheral blood.  
5. Increased secretion of IgA by GALT can stimulate intra-
inflammatory macrophage phagocytic function. 
The main purpose of prebiotics is to stimulate the growth and 
activity of beneficial bacteria in the digestive tract, which provides 
health benefits to the host. The end products of carbohydrate 
metabolism are mostly SCFA, namely acetic acid, butyric acid, and 
propionic acid, which are then used by the host as an energy source 
[47]. As a result of carbohydrate fermentation, Bifidobacterium or 
Lactobacillus can produce several compounds that inhibit the 
development of gastrointestinal pathogens, as well as cause a 
decrease in intestinal pH [48]. Furthermore, bacteria of the genus 
Bifidobacterium showed tolerance to the resulting SCFA and 
decreased pH. Because of their beneficial effect on the development 
of commensal gut bacteria, the administration of prebiotics plays a 
role in inhibiting the development of pathogens. Studies on the 
inhibition of pathogen development by prebiotics are very limited. 
In 1997 and 2003, Bovee-Oudenhoven et al. studied the use of 
lactulose in the prevention of Salmonella Enteritidis in mice. The 
results show that a decrease in intestinal pH as a result of lactulose 
fermentation leads to decreased pathogen development and 
increased translocation of pathogens from the gut [49]. 
Administration of prebiotics can also increase the absorption of 
minerals, mostly magnesium and calcium [47, 48]. 
 
Table 1: Several studies on the effects of prebiotics on inflammatory biomarkers associated with acute ischemic stroke 
Prebiotics Dose Subject Findings Reference 
Inulin 8% inulin = 
equal with 40 gr 
of fiber in 







Inulin increases the number of beneficial microbiota and decreases harmful 
microbiota in young mice feces. It also increases systemic metabolism as 
indicated by increased levels of SCFA, tryptophan-derived metabolites, bile acids, 
glycolytic metabolites, and scylloinositol. Inulin also reduces the expression of 















GOS (4 g/kg) 
for 5 w 
Mouse  - The number of Bifidobacteria after administration of FOS and GOS increased 
by 25% and 80%, respectively, compared to the number of Bifidobacteria in the 
control group 
- BDNF protein levels in the hippocampus area increased significantly in the 
group of mice given FOS compared to the GOS and control groups 
- NR1 levels increased significantly in the front cortical GOS group and the 
hippocampal FOS group 
- NR2A levels increased significantly in the GOS group in the hippocampus 
- The concentration of amino acid D-alanine and D-serine increased 
significantly in the GOS group compared to the FOS and control groups 
- Plasma PYY concentrations increased significantly in the GOS group compared 
to the FOS and control groups 
- After the administration of prebiotic GOS, there is a positive correlation 
between the number of Bifidobacteria and the levels of NR1, plasma D-alanine, 
plasma L-alanine. There is also a positive correlation between D-serine 






COS is given 
orally in 200, 
400, and 800 






COS given orally at doses of 200, 400, or 800 mg/kg is effective in improving 
learning ability and memory function. Moreover, it is also able to improve nerve 
apoptosis. The neuroprotective effect of COS is closely related to its ability to 
inhibit oxidative stress, which is shown by decreased levels of malondialdehyde 
(MDA) 8-8-hydroxy-2'-deoxyguanosine and increased levels of glutathione 
peroxidase (GPx) and superoxide dismutase (SOD) activity. COS has also been 
shown to suppress the inflammatory response by decreasing the release of 





2% GOS in the 







The administration of GOS and prebiotic yogurt GOS significantly slowed disease 
onset and prolonged life in the ALS (Amyotrophic lateral sclerosis) mice. 
Furthermore, this product increases the concentration of folate, Vitamin B12 and 
lowers homocysteine levels. GOS and yogurt prebiotics reduce the decrease in 
motor neurons, increase atrophy and mitochondrial activity in myocytes. GOS 
also suppresses the activation of astrocytes and microglia and regulates several 






13 gram B-GOS 
powder for 3 w 




Administration of bimuno-galactooligosaccharide (BGOS) reduces the 












Cortical neuronal response to NMDA iontophoresis was greater (+30%) in mice 
treated with B-GOS compared to controls not given supplementation. The intake 
of B-GOS also inhibits the reduction of the NMDA response by the glycine site 
antagonist, HA-966. Mice fed B-GOS showed greater cognitive flexibility because 








GMn 10 mg/kg 
and 20 mg/kg 




The result showed that GMn improved behavioral deficits in Parkinson’s mice. 
Additionally, glucuronomanan oligosaccharides contribute to regulating apoptotic 
signaling pathways through increased tyrosine hydroxylase (TH) expression in 
dopaminergic neurons. These results suggest that glucuronomanan oligosaccharide 
protects dopaminergic neurons from apoptosis in Parkinson’s mice. 
[58] 
Chitosan 200, 500, 1.000 mouse COS can cross the blood-brain barrier very well both in vivo and in vitro via the [59] 
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µg/kg for 12 h GLUT1 transporter. COS reduces Aβ42-mediated cytotoxicity. COS significantly 
















OMO administration can significantly improve learning abilities and memory 
function. OMO administration not only improves oxidative stress and 
inflammatory disorders but also regulate neurotransmitter synthesis and 
secretion. Histological findings suggest that administration of OPT improves 
brain tissue swelling, neuronal apoptosis, and downregulation of expression of 
the intracellular markers of Alzheimer's Disease (Tau and Aβ1-42). The 16S 
rRNA sequencing of the intestinal microbiota showed that OMO administration 
maintained the diversity and stability of the number of microbes. Furthermore, 
OMO regulates the composition and metabolism of the gut microbiota in 
inflammatory bowel disease (IBD) mice given high doses of antibiotics, thus 





10% XOS in PBS 
(phosphate 
buffer saline) 
1 ml/day for 12 w 
Wistar Mouse 
that is given 
high fat diet 
Prebiotics increased hippocampal plasticity and improved brain mitochondrial 
dysfunction in mice fed a high-fat diet. Oxidative stress and apoptosis in the 
hippocampus were significantly reduced and prebiotics also decreased 
microglial activation, thereby improving cognitive function recovery. 
[61] 
 
SCFA (Short-chain fatty acid) 
SCFA is a small organic monocarboxylic acid that has up to six carbon 
atoms chain lengths. It is the main product of anaerobic fermentation 
of indigestible polysaccharides, such as dietary fiber and resistant 
starch produced by microbiota in the large intestine [62]. Most of the 
SCFA consists of acetate (C2), propionate (C3), and butyrate [59, 60] in 
estimated molar flow rates of 60:20:2 [65], respectively. 
Approximately 500–600 mmol of SCFA is produced in the intestine per 
day, depending on dietary fiber content, microbiota composition, and 
intestinal transit time [62, 63]. Although the largest source of SCFA is 
anaerobic fermentation of fiber, acetate, propionate, and butyrate can 
also be produced from amino acid metabolism [68], where less than 
1% of the large intestinal microbiota uses this metabolic pathway to 
produce SCFA [65, 66]. Protein fermentation usually occurs in the 
distal large intestine. When carbohydrates are completely fermented, 
they lead to the production of potentially toxic metabolites, such as 
ammonia, phenols, and sulfides, as well as branched-chain fatty acids 
(BCFA) [65, 67]. The acetate produced from acetyl-CoA derived from 
glycolysis in this case can also be converted into butyl-CoA enzymes: 
acetyl-CoA transferase [68, 69], and cow's milk fat also provide a 
source of butyrate [74].  
SCFAs are absorbed by colonocytes, mainly via H+
SCFAs play a role in improving gut health by maintaining the 
integrity of the intestinal barrier, producing mucus, and providing 
protection against inflammation and thus reducing the risk of 
colorectal cancer [81–84]. Although a comprehensive understanding 
of SCFA-induced signaling is still very limited, it is well known that 
SCFA binds to G protein-coupled receptors (GPCR). The most studied 
SCFA-related receptors are GPR43 and GPR41. These two receptors 
were later renamed free fatty acid receptors (FFAR2 and FFAR3), as 
well as GPR109a/HCAR2 (hydrocarboxylic acid receptors) and 
GPR164, which are expressed in various cells, starting from the 
mucosa of the digestive tract to the immune and nervous systems 
[85, 86]. The effect of activating these receptors is very different and 
depends on the cell where the receptor is expressed. For example, 
binding of SCFA to its receptors on enteroendocrine cells results in 
the secretion of glucagon-like peptide 1 (GLP-1) and peptide YY 
(PYY) [85], while signaling on β-pancreatic cells also contributes to 
increased insulin secretion [86].  
(MCT) or sodium 
(SMCT) dependent monocarboxylate transporter [75]. MCT shows 
different subtypes and expression patterns in different tissues. SCFA 
that are not metabolized in colonocytes are transported to the portal 
circulation and used as an energy substrate for hepatocytes [76], 
except for acetate, because these acetates are not oxidized in the 
liver [76]. Therefore, only a fraction of the acetate, propionate, and 
butyrate derived from the colon reaches the systemic circulation and 
other tissues [65]. Studies on SCFA in humans are mostly influenced 
by microbes and use fecal concentration as a parameter of SCFA 
production in the large intestine [77]. Although this is a valid 
approach, there are many potential sources of bias, such as intestinal 
transit and permeability, metabolite transport, and sample handling 
[78]. Thus, all these potential sources of bias should be considered 
when inferring the effect of SCFA, given that some experiments may 
be carried out under non-physiological conditions. 
Another mechanism of SCFA in regulating systemic function is through 
inhibition of histone deacetylase (HDAC) activity, thereby promoting 
acetylation of lysine residues present in nucleosome histones in various 
cell populations [87]. This intracellular signaling mechanism has been 
found, both in the gut and associated immune tissue [88], as well as in 
the peripheral nervous system and central nervous system [87].  
The effect of SCFA on different organs and systems has now been widely 
described, although only a small fraction of SCFA in the large intestine 
reaches the systemic and tissue circulation. One of the effects of SCFA on 
the immune system is butyrate can induce Treg differentiation and 
control inflammation [73, 91-93]. Effects on activation of brown adipose 
tissue [93], regulation of liver mitochondrial function [94], body-wide 
energy homeostasis [95], and control of appetite [93] and sleep [96] 
have been associated with all types of SCFA. 
SCFA and the brain 
SCFA plays an important role in the microbiota-gut-brain 
communication process. Mobilization of SCFA in the microbiota-gut-
brain communication process is aided by the expression of MCTs in 
endothelial cells [71, 98]. SCFA can be detected in human 
cerebrospinal fluid (CSF) in the range 0–171 μM for acetate, 0–6 μM 
for propionate, and 0–2.8 μM for butyrat [98]. Butyrate levels in the 
brains of rats supplemented with Clostridium butyricum reached a 
range of 0.4 to 0.7 μmol/g, where these levels were found to be 
higher than levels in peripheral blood [26, 100]. SCFA are also 
important in maintaining the integrity of the blood-brain barrier 
related to the distribution of molecules and nutrients from the 
circulatory system to the brain. In addition, other functions of SCFA 
are related to brain development and central nervous system 
homeostasis. Evidence from research in experimental animals 
reports that SCFA can regulate the function of the blood-brain 
barrier. Germ-free mice have shown decreased expression of tight 
junction proteins, such as claudin and occludin, resulting in 
increased permeability of the blood-brain barrier from intrauterine 
life to adulthood [100]. The germ-free mice then undergo 
recolonization with a complex microbiota or monocolonization with 
butyrate-producing bacterial strains. The results obtained were that 
butyrate can improve the integrity of the blood-brain barrier [100]. 
Likewise, an in vitro study of propionate-treated cerebrovascular 
endothelial cells showed that propionate can reduce permeability 
caused by exposure to lipopolysaccharide (LPS) (LPS) [101]. 
Several studies have shown that SCFAs that enter the central 
nervous system have neuroactive properties, although the exact 
mechanism is unclear. Many animal studies have found that SCFA 
exerts a major influence on neurological function and behavior as 
well as improvements in neurodevelopmental and 
neurodegenerative disorders [73, 13, 74, 78, 103]. 
The formation of a healthy nervous system is essential for cognitive, 
emotional, and social functioning. Glial cells, especially microglia 
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cells, play an important role in the maturation and completion of the 
communication process between nerve cells [104, 105]. Therefore, 
the control of the innate immune function in the central nervous 
system is essential for brain development where the gut microbiota 
plays an important role in the immunological function of the central 
nervous system. One study explained how the microbiota could 
influence microglial maturation and function [32]. Microglia from 
mice colonized with SCFA-producing microbiota showed normal 
maturation and function, whereas non-colonized mice (given 
antibiotics) showed delayed development of microglia. Oral 
administration of a mixture of three types of SCFA consisting of 
acetate, propionate and butyrate plays a significant role in the 
maturation of microglia [32], although the mechanisms involved in 
the control of maturation and function of microglia by SCFA have yet 
to be investigated further. It is possible that FFAR2 receptor 
activation may be instrumental in this process because mouse 
microglia lacking the FFAR2 receptor were observed to be similar to 
microglia in non-colonized mice [107].  
Neuroinflammation is also an important process that affects brain 
function. Based on the results of observations in antibiotic-induced 
mice, it was found that systemic disruption of the gut microbiota by 
antibiotics resulted in changes in immune response, especially to the 
pro-inflammatory profile [32]. Neuroinflamation is also an 
important process that affects brain function. Based on observations 
in antibiotic-induced mice, systemic disruption of the gut microbiota 
by antibiotics results in altered immune responses, particularly to 
the pro-inflammatory profile [108]. This causes the central nervous 
system to become more susceptible to increased intensity of the 
inflammatory response when antibiotics eliminate all microbiota 
[108–110]. This suggests that antibiotic-induced disruption of the 
diversity of gut microbes affects inflammation of the nerve cells 
characterized by changes in microglial morphology [111–113]. In 
addition, several studies have reported that sodium butyrate is able 
to decrease microglial activation and secretion of pro-inflammatory 
cytokines [114]. Likewise, acetate administration in microglia 
primary cultures has been shown to reduce inflammation through 
decreased expression of IL-1β, IL-6, and TNF-α as well as 
phosphorylation of p38 MAPK, JNK, and NF-κB [115]. Likewise, 
acetate, which is also capable of modulating inflammatory cytokines 
and signaling pathways in the primary culture of astrocytes [116]. 
Although the mechanism of the effect of SCFA on microglia still 
requires further study, the inhibition of HDAC which epigenetically 
results in gene expression has been considered as the main effector 
mechanism induced by SCFA [117]. Thus, the role of acetylation in 
modulating glial cells is by means of anti-inflammatory and as 
neuroprotective. By considering the role of microglia in influencing 
the formation of neural tissue as well as the influence of microbiota 
on this process, SCFA may provide a new way to modulate impaired 
immunity in the brain that causes neurodevelopmental and 
neurodegenerative disorders. 
In addition to providing energy for cells and influencing the 
maturation of microglia, SCFA also affects neuron function. It has 
been described that SCFAs can modulate levels of neurotransmitters 
and neurotrophic factors. Acetate has previously been shown to 
alter levels of the neurotransmitters glutamate, glutamine and GABA 
in the hypothalamus and increase expression of anorexigenic 
neuropeptides [118]. Propionate and butyrate exert influence on 
intracellular potassium levels as evidence of the involvement of 
SCFA in the cell signaling system [119]. CFA specifically regulates the 
expression levels of tryptophan 5-hydroxylase 1, an enzyme 
involved in serotonin synthesis, and tyrosine hydroxylase, an 
enzyme involved in the biosynthesis of dopamine, noradrenaline and 
adrenaline; therefore, it produces effects on brain chemical 
components [13, 119-122]. Elimination of the microbiota by 
antibiotics can result in hippocampal neurogenesis and memory 
impairment, which can be partly reversed with the administration of 
a microbiotater and can be fully recovered with probiotic treatment 
or exercise [124]. The existence of this cognitive deficit is related to 
changes in the expression of signaling molecules that are related to 
cognition, such as brain-derived neurotrophic factor (BDNF), N-
methyl-D-aspartate receptor subunit 2B, serotonin transporter, and 
neuropeptide Y system [125].  
 
 
Fig. 3. Mechanism of SCFA in influencing gut and brain communication [98] 
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Neurotrophic factors, including nerve growth factor (NGF), glial cell 
line-derived neurotrophic factor (GDNF), and BDNF which regulate 
growth, survival and differentiation of neurons and synapses in the 
central nervous system, also play an important role in thinking and 
memory processes in various brain disorders. These factors have 
been shown to be modulated by SCFA [50, 125–127]. BDNF 
expression, neurogenesis, nerve proliferation in mice [128–130], as 
well as long-term memory consolidation can be stimulated by 
sodium butyrate [132]. Furthermore, all three types of SCFA have 
been shown to increase the growth rate of human progenitor nerve 
cells and encourage more cells to undertake mitosis [133]. This 
provides some clues as to how SCFA may regulate early nervous 
system development. SCFA exhibits effects on several neuronal 
functions, such as improving sleep cycles [96], suppressing 
orexigenic activity in neurons expressing neuropeptide Y in the 
hypothalamus [93], modulating signaling processes triggered by 
ghrelin receptors [134], as well as contributing to circadian rhythm 
and appetite control. The mechanisms involved in the modulation of 
nerve function by SCFA have revealed that some of these effects may 
be mediated by activation of the GPR41/GPR43 receptor. The effects 
of other SCFAs, particularly propionate and butyrate, are mediated 
through HDAC inhibitory activity [111, 121].  
SCFAs may directly influence the brain by strengthening BBB 
integrity, modulating neurotransmission, influencing levels of 
neurotrophic factors and increasing memory consolidation. 
However, more research is needed to understand the exact 
mechanisms involved in these neuroactive effects. 
CONCLUSION 
In recent years, research related to the gut microbiota has been 
highly developed in the biomedical field. Recent research has found 
that an imbalance in the number of probiotic and pathogenic gut 
bacteria contributes to several neurological disorders, particularly 
acute ischemic stroke. In order for probiotic bacteria to survive and 
multiply in the digestive tract, it is necessary to use prebiotics. 
Prebiotics cannot be digested by the digestive tract enzymatically so 
fermentation by probiotic bacteria in the large intestine is required 
to produce metabolites, one of which is short-chain fatty acids 
(SCFA). SCFA (short-chain fatty acids), which are the end products of 
fermentation by the intestinal microbiota, play a role in 
gastrointestinal physiology, immune function, metabolism, and even 
in the development and homeostasis of the central nervous system. 
The two-way communication that occurs between the microbiota 
and the brain can be mediated through various immunological 
mechanisms. The mechanism of microbiota-gut-brain 
communication process still needs further study, although there are 
many explanations about it. Most of the studies are still being carried 
out on experimental animals so readers should be careful when 
attributing the effects of SCFA to humans. SCFA (short-chain fatty 
acids) metabolites can modulate the microbiota-gut-brain axis 
process and have a positive impact on the brain in direct and 
indirect ways. From this process, it can further assist in developing 
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